ZBIO logo

ZBIO
Zenas Biopharma Inc.

824
Mkt Cap
$1.08B
Volume
723,653.00
52W High
$44.60
52W Low
$5.83
PE Ratio
-4.61
ZBIO Fundamentals
Price
$20.88
Prev Close
$20.16
Open
$19.76
50D MA
$33.20
Beta
1.57
Avg. Volume
347,471.64
EPS (Annual)
-$3.76
P/B
4.49
Rev/Employee
$38,461.54
Loading...
Loading...
News
all
press releases
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 7.1% - Time to Sell?
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 7.1% - Time to Sell...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas...
PR Newswire·6d ago
News Placeholder
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up After Insider Buying Activity
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up on Insider Buying Activity...
MarketBeat·9d ago
News Placeholder
Leon Moulder Jr Acquires 20,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock
Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. bought 20,000 shares of the stock in a transaction that occurred on Friday, January 9th. The stock was acquired at an...
MarketBeat·11d ago
News Placeholder
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) CEO Acquires 30,000 Shares of Stock
Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. bought 30,000 shares of Zenas BioPharma stock in a transaction dated Thursday, January 8th. The shares were acquired at an...
MarketBeat·11d ago
News Placeholder
Zenas BioPharma (NASDAQ:ZBIO) CEO Buys $819,000.00 in Stock
Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) CEO Leon Moulder, Jr. bought 50,000 shares of the firm's stock in a transaction on Wednesday, January 7th. The stock was acquired at an average...
MarketBeat·11d ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas...
PR Newswire·13d ago
News Placeholder
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study
Zenas BioPharma tanks nearly 52% despite positive INDIGO study data where obexelimab cut IgG4-RD flare risk by 56% and met all key endpoints.
Zacks·15d ago
News Placeholder
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 15.5% Following Analyst Downgrade
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 15.5% on Analyst Downgrade...
MarketBeat·15d ago
News Placeholder
Why Zenas BioPharma's Selloff Was Structurally Inevitable
read more...
Benzinga·15d ago
<
1
2
...
>

Latest ZBIO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.